EUTHYMICS BIOSCIENCE
Euthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next-generation treatments for depression. Euthymics’ initial focus is on patients who do not respond adequately to SSRIs. EB-1010 for depression is expected to improve efficacy and reduce the leading side effects associated with poor adherence to standard antidepressants including weight gain, sexual dysfunction and cognitive impairment. Euthymics is a private Delaware corporation with headquarters... in Cambridge, Massachusetts. Euthymics is developing products for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and, under a collaboration with the government, alcohol use disorder (AUD). According to the National Institutes of Health, MDD affects over 15 million American adults. According to the National Institute of Alcohol Abuse and Alcoholism (NIAAA), approximately 18 million Americans have alcohol use disorder (either alcohol dependence or alcohol abuse).
EUTHYMICS BIOSCIENCE
Social Links:
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2009-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.euthymics.com
Total Employee:
11+
Status:
Active
Contact:
617-758-0300
Email Addresses:
[email protected]
Total Funding:
38.5 M USD
Technology used in webpage:
Facebook Sharer Pinterest New Relic WhatsApp OVH Facebook Like Button Plesk Citrix NetScaler ClouDNS Kk Star Ratings
Current Advisors List
Current Employees Featured
Founder
Investors List
GBS Ventures
GBS Ventures investment in Series A - Euthymics Bioscience
H&Q Venture Capital
H&Q Venture Capital investment in Series A - Euthymics Bioscience
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Euthymics Bioscience
Venture Investors
Venture Investors investment in Series A - Euthymics Bioscience
Hambrecht & Quist Capital Management
Hambrecht & Quist Capital Management investment in Series A - Euthymics Bioscience
GBS Ventures
GBS Ventures investment in Series A - Euthymics Bioscience
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Euthymics Bioscience
Official Site Inspections
http://www.euthymics.com
- Host name: 104.21.43.153
- IP address: 104.21.43.153
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Euthymics Bioscience"
Euthymics Bioscience Company Profile 2024: Valuation, …
Euthymics Bioscience is headquartered in Cambridge, MA. What is the size of Euthymics Bioscience? Euthymics Bioscience has 13 total employees. What industry is Euthymics Bioscience in? Euthymics Bioscience’s primary industry …See details»
Euthymics Bioscience, Inc. Company Profile - Dun & Bradstreet
Company Description: Euthymics Bioscience wants to put patients in a pleasant state of mind. Named for a medical term defined as a moderate mood that's neither manic nor depressed, …See details»
Organization | Euthymics BioScience, Inc.
Euthymics BioScience, Inc. Report issue For profit Phase 3 Founded: Cambridge MA United States (2009)See details»
Euthymics Bioscience Inc - Company Profile and News
Euthymics Bioscience, Inc. develops biopharmaceutical products. The Company offers products such as anti-depressant for major depressive disorder, as well as norepinephrine and dopamine.See details»
Euthymics - Overview, News & Similar companies | ZoomInfo.com
Euthymics is a company that operates in the Cosmetics industry. It employs 11-20 people and has $1M-$5M of revenue. The company is headquartered in Cambridge, Massachusetts. Read …See details»
Euthymics Bioscience - Products, Competitors, Financials, …
Euthymics Bioscience's latest funding round is Acquired. How much did Euthymics Bioscience raise? Euthymics Bioscience raised a total of $28.33M. Who are the investors of Euthymics …See details»
Euthymics Bioscience, Inc.: Contact Details and Business Profile
Euthymics Bioscience, Inc. is a Biotechnology, Neuropsychiatric drug development, and Pharmaceuticals company located in Cambridge, Massachusetts with 1 employees. Find top …See details»
Euthymics Bioscience - Funding, Financials, Valuation & Investors
Euthymics Bioscience is funded by 6 investors. GBS Ventures and H&Q Venture Capital are the most recent investors. Euthymics Bioscience has a post-money valuation in the range of …See details»
Euthymics Bioscience - Contacts, Employees, Board Members
Organization. Euthymics Bioscience . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of …See details»
Euthymics Bioscience - VentureRadar
Euthymics’ management team is a group of experienced drug developers with a track record of success in neuroscience product development. We are dedicated to providing better …See details»
Euthymics Bioscience - Tech Company Profile - Gaebler.com …
Euthymics Bioscience is a leading biopharmaceutical company, located in Cambridge. Financial backing was provided by private investors, Novartis Venture Fund and Hambrecht & Quist …See details»
Euthymics’s Competitors, Revenue, Number of Employees ... - Owler
Euthymics’s Profile, Revenue and Employees. Euthymics Bioscience is a neuroscience-focused biopharmaceutical company that develops medicines for depressive disorders. Euthymics’s …See details»
Euthymics - Company Profile - Tracxn
Oct 21, 2024 Euthymics - Medicine for alcohol use disorder (AUD) and smoking cessation.. This company is not active anymore. Raised a total funding of $41.5M over 4 rounds from 6 …See details»
Business Profile for Euthymics Bioscience, Inc. - Better Business …
This organization is not BBB accredited. Pharmaceutical Research in Cambridge, MA. See BBB rating, reviews, complaints, & more.See details»
Euthymics Bioscience - Updates, News, Events, Signals & Triggers
Euthymics Bioscience, a neuroscience-focused biopharmaceutical company, develops medicines for central nervous system disorders.See details»
ETHISMOS RESEARCH INC. CLOSES DEAL — Ethismos Research, Inc
Nov 1, 2017 Mr. McKinney has a strong background working with amitifadine since he was founding CEO of Euthymics starting in 2010. He also served as founding CEO of Neurovance …See details»
DOV-102677 - Drug Targets, Indications, Patents - Synapse
Dec 6, 2024 Background: Concurrent inhibitors of dopamine, norepinephrine, and serotonin uptake have been proposed as novel antidepressants. Given the high comorbidity between …See details»
Walter Piskorski - COO @ Euthymics Bioscience - Crunchbase
Walter Piskorski is the COO at Euthymics Bioscience. Additionally, Walter Piskorski has had 4 past jobs including COO at Neurovance. Euthymics Bioscience COO. Organization Name . …See details»